I also want to thank the authors for being open to questions and answering them so thoroughly.
My question is in relation to the safety variables... Patients who were in the Intervention group were significantly more likely to develop a new ischemic stroke in a different vascular territory (p<0.001). Were these patients provided follow-up treatment, and if so, which one? Are there any hypotheses as to what can be administered post-treatment to prevent these adverse events? (The U.S.'s current healthcare policy punishes hospitals for high readmission rates).